Wetherby Asset Management Inc. boosted its position in Becton Dickinson and Co (NYSE:BDX) by 28.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 8,433 shares of the medical instruments supplier’s stock after acquiring an additional 1,848 shares during the quarter. Wetherby Asset Management Inc.’s holdings in Becton Dickinson and were worth $1,805,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently made changes to their positions in the company. Legacy Advisors LLC increased its holdings in Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 490 shares in the last quarter. FTB Advisors Inc. increased its holdings in Becton Dickinson and by 114.2% in the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 290 shares in the last quarter. Penserra Capital Management LLC purchased a new position in Becton Dickinson and in the fourth quarter valued at about $136,000. Exane Derivatives increased its holdings in Becton Dickinson and by 848.6% in the fourth quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after buying an additional 628 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Becton Dickinson and in the fourth quarter valued at about $160,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.
BDX has been the subject of a number of research analyst reports. Argus increased their target price on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Wells Fargo & Co reissued a “positive” rating and set a $235.00 price objective (up from $225.00) on shares of Becton Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. KeyCorp began coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Bank of America reissued a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Morgan Stanley raised their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $237.27.
Shares of Becton Dickinson and Co (NYSE:BDX) opened at $222.87 on Tuesday. The company has a market cap of $59,337.46, a P/E ratio of 170.13, a price-to-earnings-growth ratio of 1.59 and a beta of 1.12. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. Becton Dickinson and Co has a 12 month low of $175.66 and a 12 month high of $248.39.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. Becton Dickinson and’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.33 EPS. equities analysts anticipate that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be paid a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a yield of 1.35%. Becton Dickinson and’s payout ratio is currently 229.01%.
In other Becton Dickinson and news, Director Timothy M. Ring sold 269,661 shares of Becton Dickinson and stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by insiders.
WARNING: “Becton Dickinson and Co (BDX) Position Raised by Wetherby Asset Management Inc.” was posted by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/20/becton-dickinson-and-co-bdx-position-raised-by-wetherby-asset-management-inc.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.